InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
56,882.70
(
-2.43%
)
Post# of 252501
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119983
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: BioSpecialist post# 60342

Friday, 03/14/2008 1:51:15 AM

Friday, March 14, 2008 1:51:15 AM

Post# of 252501
MNTA is working on a generic version of Lovenox.

If new clinical data were to come out that greatly encouraged docs to prescribe Arixtra, that could conceivably have some impact on the market for generic (and branded) Lovenox. But the results you speak of are not new; in fact, I’ve already posted them myself on this board.

Whatever the reason, Arixtra continues to be a commercial dog and FDA approval of a generic is not going to change that all by itself.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up